Company news
Galmed Pharmaceuticals Ltd. news in 2023
Galmed Pharmaceuticals Ltd.'s news releases, calls and decks from 2023, newest first.
Galmed Pharmaceuticals: Consolidated Financial Statements - Form 6-K
November 22, 2023
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
November 19, 2023
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
September 25, 2023
16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K
August 9, 2023
Securities Purchase Agreement - Form 6-K
July 18, 2023
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
July 13, 2023
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
July 9, 2023
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
May 31, 2023
Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
May 8, 2023
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
March 28, 2023
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
February 7, 2023
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
January 3, 2023